A preclinical study found that repeated CBG treatment prevented a long-term recognition memory impairment induced by MK-801 in male rats, an experimental model used to study cognitive deficits relevant to schizophrenia. The effect did not appear to involve restoring reduced BDNF protein levels, though changes in TrkB messenger RNA point to a possible mechanism that… Keep Reading
A four-person Johns Hopkins pilot study found that 25 mg of oral THC could produce altered-state profiles that qualitatively resembled those seen with 25 mg of psilocybin, particularly when consumed in a setting modeled on psychedelic research. The sample is far too small to establish cannabis as a psychedelic, but the findings add to earlier… Keep Reading
In 1994, Melanie Dreher published a study showing that cannabis-exposed babies thrived. The medical establishment went silent. Thirty years later, she’s still trying to finish the work — and pregnant women are still being jailed. More than 25 years ago, a landmark study quietly challenged one of modern medicine’s most deeply rooted assumptions: Cannabis use… Keep Reading
Dr. Dana Lambert left hospital pharmacy in 2013 to study cannabinoid pharmacology, learned plant medicine from indigenous elders, and bet her career on the whole plant. A new Oxford-published study shows two cannabinoids most dispensary customers have never asked for, CBC and CBG, can make silver work 64 times harder against MRSA, E. coli and… Keep Reading
A PAX-authored study comparing vaporized cannabis to joint smoke found significantly lower levels of certain compounds under controlled lab conditions. A new research paper is adding fresh data to a long-running question in cannabis consumption: how vaporizing compares to smoking when it comes to chemical exposure. The research—conducted by Richard Rucker, who serves as PAX’s… Keep Reading
